After the transition is complete, Caforio will continue as chair of Bristol Myers’ board of directors, although it is not typical for U.S-based drugmakers to permanently split the CEO and board chair roles. The company said his tenure as chair will be “for a transition period to be determined by the board.”
Taking Boerner’s place as chief commercial officer will be Adam Lenkowsky, currently Bristol Myers’ head of major markets. That transition is effective immediately with Boerner’s elevation to COO.
A medical doctor, Caforio assumed the CEO’s role from Lamberto Andreotti in 2015 after having worked in numerous roles across the company, including as chief commercial officer and COO.
His tenure as Bristol Myers chief was defined by the company’s development of the blood thinner Eliquis and the cancer immunotherapy Opdivo into blockbuster medicines, as well as a string of big-ticket acquisitions, most notably a $74 billion acquisition of Celgene. That deal brought in the fast-selling blood cancer treatment Revlimid, making Bristol Myers one of the largest oncology companies, as well as the cancer cell therapies Abecma and Breyanzi, which now figure more prominently in its plans.
Yet Bristol Myers also misstepped under Caforio, choosing a clinical development plan for Opdivo that backfired and allowed rival Merck & Co. to take a leading position in the market for cancer immunotherapies. A big bet on an experimental immunotherapy developed by biotechnology company Nektar Therapeutics also didn’t pan out. READ MORE
By Jonathan Gardner
Source: biopharmadive.com
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.
DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.
Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.
